NEWARK, Del.--(BUSINESS WIRE)--Strategic Diagnostics Inc. (Nasdaq:SDIX) – today announced that project bookings for “custom” Genomic Antibody Technology® (GAT) projects exceeded the $1 million dollar mark over the last seven months of 2007. The full-range of GAT offerings were introduced in May of 2007. Since that introduction, the Company has received orders from more than 100 customers including eight of the top 18 pharmaceutical/biotech companies (as ranked by global revenue).
